3 Medical Device, Surface Chemical and Helmet Stocks With a Strong Future Roadmap: Poly Medicure, Grauer & Weil (India) and Studds Accessories

Poly Medicure Rs 1,593.80, P/E 51.87. Grauer & Weil Rs 78.83, P/E 22.12. Studds Rs 407.15, P/E 21.92. Closing prices of 14 Oct 2026.

Updated: 19 Oct 2026 • 2:31 pm

Posted by:

3 Medical Device, Surface Chemical and Helmet Stocks With a Strong Future Roadmap: Poly Medicure, Grauer & Weil (India) and Studds Accessories

Quick Answer

Medical device, surface chemical and helmet stocks with the clearest long-term roadmaps today include Poly Medicure in medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets, Grauer & Weil in surface treatment chemicals and related industrial products and Studds in motorcycle helmets and riding accessories sold in India and overseas. FY26 revenue growth was 13.4% at Poly Medicure, 5.1% at Grauer & Weil and 8.4% at Studds. P/E stands at 51.87 for Poly Medicure (industry 62.79), 22.12 for Grauer & Weil (industry 36.60) and 21.92 for Studds (industry 36.50). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Medical device, surface chemical and helmet stocks give investors exposure to hospital supplies, industrial chemicals and safety gear. Volumes, export demand and margins decide how much of that demand turns into profit.

This list covers three medical device, surface chemical and helmet stocks: Poly Medicure for medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets, Grauer & Weil (India) for surface treatment chemicals and related industrial products and Studds Accessories for motorcycle helmets and riding accessories sold in India and overseas. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Medical Device, Surface Chemical and Helmet Stocks?

Medical device, surface chemical and helmet stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Medical Device, Surface Chemical and Helmet Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three medical device, surface chemical and helmet stocks as of the 14 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Poly Medicure	1,593.80	16,231	51.87	62.79	10.37%	0.11
Grauer & Weil (India)	78.83	3,540	22.12	36.60	15.16%	0.01
Studds Accessories	407.15	1,637	21.92	36.50	15.80%	0.02

Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.

Why Do Medical Device, Surface Chemical and Helmet Stocks Have a Strong Roadmap in India?

Medical device, surface chemical and helmet stocks have a strong roadmap in India because hospital device demand, manufacturing output and two-wheeler ownership keep adding volumes for these firms. Three drivers stand out.

Hospital demand: Hospitals buy infusion, catheter and dialysis products.
Manufacturing output: Factories use surface treatment chemicals.
Two-wheeler riders: Safety rules and rising incomes lift helmet demand.

Poly Medicure: Medical Devices Build the Next Leg

Poly Medicure's roadmap rests on medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets, with rising healthcare consumption and export demand supporting growth.

Revenue grew from Rs 960.97 crore in FY22 to Rs 1,995.34 crore in FY26, a 107.6% rise, and FY26 revenue was 13.4% higher than FY25. FY26 net profit was Rs 320.73 crore. In Q1 FY27, revenue grew 25.5% to Rs 558.79 crore. Operating margin was 27.65% in FY26.

Debt to equity is 0.11 and return on equity is 10.37%. FY26 operating cash flow was Rs 246.37 crore against capital expenditure of Rs 308.39 crore. Poly Medicure paid a dividend of Rs 3.5 per share for FY26, a yield of 0.22%. At a P/E of 51.87 against an industry P/E of 62.79, the stock trades below its industry multiple.

What to watch: The P/E of 51.87 against an industry P/E of 62.79 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Grauer & Weil (India): Surface Treatment Chemicals Drive the Pipeline

Grauer & Weil's roadmap rests on surface treatment chemicals and related industrial products, with several business lines supporting earnings.

Revenue grew from Rs 782.11 crore in FY22 to Rs 1,239.78 crore in FY26, a 58.5% rise, and FY26 revenue was 5.1% higher than FY25. FY26 net profit rose 4.3% to Rs 164.03 crore. Over four years, net profit rose from Rs 78.77 crore in FY22 to Rs 164.03 crore. In Q1 FY27, revenue grew 17.0% to Rs 311.11 crore. Operating margin was 18.87% in FY26.

Debt to equity is 0.01 and return on equity is 15.16%. FY26 operating cash flow was Rs 151.86 crore against capital expenditure of Rs 53.65 crore. Grauer & Weil paid a dividend of Rs 1 per share for FY26, a yield of 1.28%. At a P/E of 22.12 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: The P/E of 22.12 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Studds Accessories: Helmets and Riding Gear Build the Next Leg

Studds' roadmap rests on motorcycle helmets and riding accessories sold in India and overseas, with rising two-wheeler use and safety awareness supporting volumes.

Revenue grew from Rs 467.98 crore in FY22 to Rs 645.75 crore in FY26, a 38.0% rise, and FY26 revenue was 8.4% higher than FY25. FY26 net profit rose 18.7% to Rs 82.65 crore. Over four years, net profit rose from Rs 28.64 crore in FY22 to Rs 82.65 crore. In Q1 FY27, revenue grew 13.8% to Rs 172.92 crore. Operating margin was 21.25% in FY26.

Debt to equity is 0.02 and return on equity is 15.80%. FY26 operating cash flow was Rs 86.42 crore against capital expenditure of Rs 47.04 crore. Studds paid a dividend of Rs 3 per share for FY26, a yield of 0.72%. At a P/E of 21.92 against an industry P/E of 36.50, the stock trades below its industry multiple.

What to watch: The P/E of 21.92 against an industry P/E of 36.50 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Best Medical Device, Surface Chemical and Helmet Stocks in India: Poly Medicure vs Grauer & Weil vs Studds on Key Financials

Among the best medical device, surface chemical and helmet stocks in India, Poly Medicure leads on FY26 revenue growth and FY26 operating margin; Grauer & Weil leads on the lowest debt to equity and dividend yield; Studds leads on return on equity and the lowest P/E. The table puts the numbers side by side.

Metric	Poly Medicure	Grauer & Weil	Studds
FY26 revenue (Rs Cr)	1,995.34	1,239.78	645.75
FY26 revenue growth	13.4%	5.1%	8.4%
FY26 net profit (Rs Cr)	320.73	164.03	82.65
FY26 operating profit margin	27.65%	18.87%	21.25%
Q1 FY27 revenue growth (YoY)	25.5%	17.0%	13.8%
Return on equity	10.37%	15.16%	15.80%
P/E ratio	51.87	22.12	21.92
Debt to equity	0.11	0.01	0.02
Dividend yield	0.22%	1.28%	0.72%
FY26 operating cash flow (Rs Cr)	246.37	151.86	86.42

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Medical Device, Surface Chemical and Helmet Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen medical device, surface chemical and helmet stocks and shortlist medical device, surface chemical and helmet stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check revenue growth, operating margin and cash flow together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these medical device, surface chemical and helmet stocks

Risks to Consider Before Investing in Medical Device, Surface Chemical and Helmet Stocks

Consumer demand: Spending patterns can shift sales between quarters.
Input costs: Changes in raw material prices can affect margins.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Poly Medicure, Grauer & Weil and Studds live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover medical devices, surface chemicals and helmets. Poly Medicure leads on FY26 revenue growth and FY26 operating margin; Grauer & Weil leads on the lowest debt to equity and dividend yield; Studds leads on return on equity and the lowest P/E.

Across medical device, surface chemical and helmet stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the medical device, surface chemical and helmet stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Medical Device, Surface Chemical and Helmet Stocks

Which are the best medical device, surface chemical and helmet stocks in India with a strong roadmap?

Ans. Poly Medicure, Grauer & Weil (India) and Studds Accessories stand out for their roadmaps in medical devices, surface chemicals and helmets. FY26 revenue growth was 13.4% at Poly Medicure, 5.1% at Grauer & Weil and 8.4% at Studds, and return on equity ranges from 10.37% to 15.80%.

Is Poly Medicure a good stock to buy now?

Ans. Poly Medicure has a debt to equity ratio of 0.11, a return on equity of 10.37% and a P/E of 51.87 against an industry P/E of 62.79. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Poly Medicure, Grauer & Weil and Studds?

Ans. The P/E ratio is 51.87 for Poly Medicure (industry 62.79), 22.12 for Grauer & Weil (industry 36.60) and 21.92 for Studds (industry 36.50). All of them trade below the industry multiple.

Which of these medical device, surface chemical and helmet stocks has the highest return on equity?

Ans. Studds Accessories has the highest return on equity at 15.80%, followed by Grauer & Weil (India) at 15.16% and Poly Medicure at 10.37%.

What are the risks of investing in medical device, surface chemical and helmet stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Poly Medicure, Grauer & Weil and Studds perform in Q1 FY27?

Ans. Poly Medicure reported revenue of Rs 558.79 crore, up 25.5% year on year. Grauer & Weil (India) reported revenue of Rs 311.11 crore, up 17.0% year on year. Studds Accessories reported revenue of Rs 172.92 crore, up 13.8% year on year.

Do medical device, surface chemical and helmet stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.22% for Poly Medicure, 1.28% for Grauer & Weil and 0.72% for Studds, based on dividends declared for FY26.

How can I invest in medical device, surface chemical and helmet stocks in India?

Ans. You can buy medical device, surface chemical and helmet stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.